Skip to main content
Premium Trial:

Request an Annual Quote

Nassim Usma, Paul M. Meister

Premium
RXi Pharmaceuticals this week announced that Nassim Usman has joined its scientific advisory board. Usman is currently CEO and a director of Catalyst Biosciences. Prior to joining Catalyst, he was an entrepreneur-in-residence at Morgenthaler Ventures.
 
Usman previously held several positions during his 13-year tenure at Sirna. Usman is currently a member of the scientific advisory board of Noxxon Pharma.
 

 
Thermo Fisher Scientific this week announced that Paul M. Meister, chairman of the board and former vice chairman of Fisher Scientific International, decided to retire from the company’s board of directors. 
 
The company also announced that Meister has relinquished his position as chairman of the board.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.